When compared with homozygosity, heterozygosity at one HLA‐I locus could significantly enhance clinical outcomes in NSCLC or melanoma patients who received anti‐CTLA‐4 or anti‐PD‐1 therapies.41 This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.